ArticleScientific reports2017
Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes.European journal of nuclear medicine and molecular imaging · 2026Article
- Role of tumor markers before or during chemotherapy for digestive neuroendocrine carcinomas as an exploratory analysis of JCOG1213.Scientific reports · 2026Article
- Prognostic Role of Inflammatory Biomarkers in Gastrointestinal Neuroendocrine Neoplasms: A Cross-Sectional Study.Health science reports · 2025Article
- Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.British journal of cancer · 2025Article
- Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study.EClinicalMedicine · 2025Article
- Machine learning predicts prognosis in patients with gastroenteropancreatic neuroendocrine tumors with liver metastases.Discover oncology · 2025Article
- Atypical Presentation of Small Bowel Neuroendocrine Carcinoma Leading to Acute Obstruction.Cureus · 2025Article
- Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.Journal of neuroendocrinology · 2024Article
- Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma.Journal of gastrointestinal oncology · 2024Article
- Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.Internal medicine (Tokyo, Japan) · 2024Article
- Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma.BMC cancer · 2023Article
- Pure small cell neuroendocrine carcinoma of urinary bladder: A case report.Clinical case reports · 2022Article
- Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma.Chonnam medical journal · 2022Article
- Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study.Cancer management and research · 2021Article
- P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.BMC cancer · 2020Article
- Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method.Journal of medical imaging (Bellingham, Wash.) · 2020Article
- Neuroendocrine Carcinoma of Duodenum-an Uncommon Tumour at an Unusual Site.Indian journal of surgical oncology · 2019Article
- C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group.World journal of gastrointestinal oncology · 2019Article
- Grading of Neuroendocrine Carcinomas: Correlation ofDisease markers · 2018Article
- EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are a very aggressive type of cancer, for which prognostic factors are lacking. We analysed clinical and histomorphological prognostic markers of overall survival (OS), completed with a record of biological and haematological data of patients diagnosed between December 2002 and December 2015. The median OS was 16 months (95% CI 13.9-18.1). After univariate analysis, performance status (PS) ≥ 2 and stage IV were associated with a worse outcome (9 months and 14 months, respectively), as well as patients with lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) levels ≥ 2 ULN (9 months and 8 months, respectively). After multivariate analysis, LDH and AST levels were the only factors that remained significantly associated with better survival: HR 0.36 (p = 0.04) and 0.31 (p = 0.03), respectively. When patients had elevated LDH and AST levels, OS was 20 months, when they had high LDH or AST levels, 13 months and 8 months in the group with low LDH and AST levels (p < 0.001). Therefore, biological data appeared to be more relevant prognostic factors than usual factors described in other studies (PS, stage, and Ki-67). Considering LDH and AST levels at diagnosis could help physicians to predict survival and to stratify patients for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.